Home > Oncology > ESMO 2021 > COVID-19 > Adequate response to SARS-CoV-2 vaccine in cancer patients

Adequate response to SARS-CoV-2 vaccine in cancer patients

Presented By
Dr Sjoukje Oosting, University Medical Center Groningen, the Netherlands & Dr Scott Shepherd, Royal Marsden NHS Foundation Trust, UK
Conference
ESMO 2021
Trial
VOICE & CAPTURE
Results from both the VOICE and CAPTURE study showed that cancer patients in general have an adequate response to SARS-CoV-2 infection and/or SARS-CoV-2 vaccination. Patients with cancer have an increased risk of complications from SARS-CoV-2 infection [1]. Vaccination is recommended, but the impact of chemotherapy and immunotherapy on immunogenicity and safety is still unclear [2]. The prospective, multicentre, non-inferiority VOICE trial (NCT04715438) aimed to assess the impact of immunotherapy, chemotherapy, and chemo-immunotherapy on immunogenicity and safety of SARS-CoV-2 vaccination in patients treated for a solid tumour [3]. VOICE compared 4 cohorts: individuals without cancer (A) and patients with solid tumours who were treated with immunotherapy (B), chemotherapy (C), or chemo-immunotherapy (D). Participants received 2 mRNA-1273 vaccinations 28 day...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on